Browsing by Author "Calderon-Valencia, G"

Now showing 1 - 3 of 3

Correction to: Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute (Annals of Surgical Oncology, (2024), 31, 9, (6097-6117), 10.1245/s10434-024-15573-6)
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
In the original online version of this article Luis Piedra‑Delgado's affiliation was incorrect. It is correct as reflected here. The original article was corrected.
Human Papillomavirus, Cytomegalovirus Infection and P16 Staining in Breast Tumors from Peruvian Women
(Asian Pacific Organization for Cancer Prevention, 2022) Calderon-Valencia, G; Castaneda-Altamirano, C; Castillo, M; Sanchez, J; Bernabe, L; Suarez, N; Tello, K; Torres, E; Cotrina-Concha, JM; Dunstan Yataco, J; De-La-Cruz-Sacasqui, M; Abugattas Saba, J; Guerra Miler, H; Manrique Hinojosa, E; Aguayo, F; Gomez Moreno, HL
Objective: To evaluate the frequency distribution of viral infections in Peruvian Breast Cancer (BC) lesions and its association with clinicopathological features. Additionally, a prospective evaluation of p16 and Tumor-infiltrating lymphocytes (TIL) levels were performed for developing a comprehensive analysis. Methods: Detection of high risk- human papillomavirus (HR- HPV) through qPCR was performed in 447 BC and 79 non-cancer frozen samples. Paired paraffin samples from 238 BC were stained with Human cytomegalovirus (HCMV) and p16 immunohistochemistry. TIL was calculated in 397 BC cases. Results: HCMV was positive in 72.5%. HR- HPV was detected in 2.9% of BC and 1.3% of non-malignant samples. P16+ was found in 28.15% and median TIL percentage was 30. HR- HPV infection was associated with non-ductal histology (p=0.003) and p16+ (p=0.017). Positive P16+ was associated with higher T stage (p=0.022), grade (p=0.009), TIL level (p=0.002), and triple-negative phenotype (p=0.021). Conclusion: HCMV is frequent, but HR- HPV infection is unusual in Peruvian BC. P16+ is associated with HR- PVH infection, high TIL and aggressive features. © 2022. All Rights Reserved.
Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
Introduction: The worldwide incidence of melanoma has increased in the last 40 years. Our aim was to describe the clinic-pathological characteristics and outcomes of three cohorts of patients diagnosed with melanoma in a Latin-American cancer institute during the last 20 years. Methods: We evaluated three retrospective patient cohorts diagnosed with melanoma at Instituto Nacional de Enfermedades Neoplasicas (INEN), a public hospital in Lima, Peru, for the years 2005–2006, 2010–2011, and 2017–2018. Survival rate differences were assessed using the Log-rank test. Results: Overall, 584 patients were included (only trunk and extremities); 51% were male, the mean age was 61 (3–97) years, and 48% of patients resided in rural areas. The mean time to diagnosis was 22.6 months, and the mean Breslow thickness was 7.4 mm (T4). Lower extremity was the most common location (72%). A majority of the patients (55%) had metastases at the time of presentation, with 36% in stage III and 19% in stage IV. Cohorts were distributed as 2005–2006 (n = 171), 2010–2011 (n = 223), and 2017–2018 (n = 190). No immunotherapy was used. Cohort C exhibited the most significant increase in stage IV diagnoses (12.3%, 15.7%, 28.4%, respectively; p < 0.01). The median overall survival rates at the three-year follow-up demonstrated a decline over the years for stages II (97%, 98%, 57%, respectively; p < 0.05) and III (66%, 77%, 37%; p < 0.01). Conclusions: There has been a worsening in the incidence of late-stage metastatic melanoma in Peru throughout the years, coupled with a significant decline in overall survival rates. This is underscored by the fact that half of the population lives in regions devoid of oncological access.